Increased Finance Receivables Portfolio
The gross finance receivables portfolio increased 15% year-over-year to $270 million, with a third quarter portfolio effective yield improving by 60 basis points year-over-year to 14.6%.
Revenue Growth
Segment revenue increased 13.5% year-over-year to $10 million with a realized yield of 13.8%.
Successful Transactions and Deals
Closed an up to $11 million royalty monetization with Relief Therapeutics and a $26 million upsized amendment to Eton Pharmaceuticals.
Enteris Division Progress
Enteris division's revenue doubled to $600,000 this quarter, with fourth quarter quarter-to-date bookings at an all-time high.
Resolution of Nonaccruals
Significant progress made in working out three nonaccrual names, including Exeevo and BIOLASE, without expected impairments.